SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-23-027396
Filing Date
2023-05-31
Accepted
2023-05-31 07:55:21
Documents
13
Period of Report
2023-05-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc20053533_8k.htm   iXBRL 8-K 34584
2 EXHIBIT 10.1 brhc20053533_ex10-1.htm EX-10.1 488248
  Complete submission text file 0001140361-23-027396.txt   778637

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atai-20230526.xsd EX-101.SCH 3856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atai-20230526_lab.xml EX-101.LAB 23290
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atai-20230526_pre.xml EX-101.PRE 16546
7 EXTRACTED XBRL INSTANCE DOCUMENT brhc20053533_8k_htm.xml XML 4214
Mailing Address 524 BROADWAY NEW YORK NY 10013
Business Address WALLSTRASSE 16 BERLIN 2M 10179 (617)-699-5876
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

IRS No.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40493 | Film No.: 23978978
SIC: 2834 Pharmaceutical Preparations